Navigation Links
Amarin to Present at the Deutsche Bank 26th Annual Healthcare Conference
Date:4/26/2011

MYSTIC, Conn. and DUBLIN, April 26, 2011 /PRNewswire/ -- Amarin Corporation plc (Nasdaq: AMRN), a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today announced that John Thero, Amarin's President, will present at the Deutsche Bank 26th Annual Healthcare Conference to be held at the InterContinental Hotel in Boston. The presentation will take place at 2:10 p.m. on May 3, 2011. A live Webcast of the presentation will be available at the following URL:

http://www.corporate-ir.net/ireye/confLobby.zhtml?ticker=AMRN&item_id=3912202

About Amarin

Amarin Corporation plc is a clinical-stage biopharmaceutical company with expertise in lipid science focused on the treatment of cardiovascular disease. The Company's lead product candidate is AMR101 (icosapent ethyl). The Company reported positive, statistically significant top-line results for both of its two pivotal Phase 3 clinical trials, the MARINE trial (investigation of AMR101 as a treatment for patients with very high triglycerides [>500 mg/dL]), as reported on November 29, 2010 and the ANCHOR trial (investigation of AMR101 for the treatment of patients on statin therapy with high triglycerides [>200 and <500mg/dL] with mixed dyslipidemia), as reported on April 18, 2011. Both the MARINE and the ANCHOR trials were conducted under Special Protocol Assessment (SPA) agreements with the U.S. Food and Drug Administration (FDA). Amarin also has next-generation lipid candidates under evaluation for preclinical development.

Investor Contact Information:
Stephen D. Schultz
Investor Relations and Corporate Communications
Amarin Corporation
In U.S.: +1 (860) 572-4979 x292
investor.relations@amarincorp.com

Lee M. Stern
The Trout Group
In U.S.: +1 (646) 378-2922
lstern@troutgroup.com

Media Contact Information:
David Schull or Martina Schwarzkopf, Ph.D.
Russo Partners
In U.S.: +1 (212) 845-4271 or +1 (212) 845-4292 (office)
+1 (347) 591-8785 (mobile)
david.schull@russopartnersllc.com
martina.schwarzkopf@russopartnersllc.com


'/>"/>
SOURCE Amarin Corporation plc
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Amarin Proceeding to Phase 3 With AMR101 for Hypertriglyceridemia
2. Amarin Corporation Appoints Colin W. Stewart as President and Chief Executive Officer
3. Amarin to Present at UBS Life Sciences Conference
4. Amarin Corporation to Host Investor Conference Call on Wednesday, November 10, 2010
5. Amarin to Present at Canaccord Genuity Cardiovascular, Diabetes & Obesity Conference
6. Amarin Prices Public Offering of American Depositary Shares
7. Amarin Announces Underwriters Exercise of Over-Allotment Option
8. Amarin Announces Successful Completion of Offering of American Depositary Shares
9. Amarin Provides 2010 Year-End Review to Shareholders
10. Amarin to Present at the Leerink Swann Hot Topics in Therapeutics Roundtable Conference
11. Amarin to Present at Two Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/7/2017)...   BioLife Solutions , Inc. (NASDAQ: BLFS ... grade cell and tissue hypothermic storage and ... , President and CEO, will be presenting at two investment ... Renshaw 19 th Annual Global Investment Conference on Tuesday, ... time). The conference is being held at the New York ...
(Date:9/6/2017)... , Sept. 6, 2017   PDI , a ... it will host an educational session focused on the ... infection (CLABSI) prevention at the 2017 Annual Scientific Meeting ... will take place at the Phoenix ... from Sept. 16-19, will also feature PDI,s ...
(Date:9/5/2017)... -- Sapheneia and Scannerside received FDA 510(k) clearance to ... third-party Vendor neutral CT product that makes it affordable ... current MITA standards. ... specifically designed to provide CT operators, prior to a ... a predefined threshold. Scannerside Dose Check is intended to ...
Breaking Medicine Technology:
(Date:9/21/2017)... Falls Church, VA (PRWEB) , ... September 21, ... ... Use Policy , **An FDAnews Management Report**, http://www.fdanews.com/products/54818-promotional-communication      , In the ... every edge they can get while staying in compliance with FDA rules. , ...
(Date:9/21/2017)... WA (PRWEB) , ... September 21, 2017 , ... ... technology using Microscan’s LVS 7510 at the Global GS1 Healthcare Conference 2017 in ... of the life-sciences industry for ensuring label quality and improving patient safety. ...
(Date:9/21/2017)... ... September 21, 2017 , ... FlipBelt, the fitness brand that ... detail to the athletic wear market with the launch of their FlipBelt Crops. , ... their essentials securely at their fingertips while at the gym, on the trail, or ...
(Date:9/20/2017)... ... September 20, 2017 , ... FirstAlign ( http://www.firstalign.com ), combines ... Artificial Intelligence (AI) thinking, announced today the launch of its revamped web presence. ... information that offers a more comprehensive understanding of the organization’s business and machine ...
(Date:9/20/2017)... ... September 20, 2017 , ... ... and commercialization, has just released a new white paper discussing the benefits ... than ever about medical device, pharmaceutical, and combination product organizations making sure ...
Breaking Medicine News(10 mins):